Psychedelic-assisted therapy information hub

11 May 2023

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has developed a Psychedelic-Assisted Therapy Information Hub to provide information to mental health professionals on medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) for the treatment of mental health conditions.

RANZCP has established the hub to provide relevant information to other healthcare professionals and the broader community about psychedelic-assisted therapy.

The hub contains…

  • An updated clinical memorandum on the therapeutic use of psychedelic substances

  • Guidance for potential prescribers

  • FAQs

In Australia, the Therapeutic Goods Administration (TGA) has permitted the use of MDMA and psilocybin for the treatment of certain mental health conditions.

From 1 July 2023, authorised psychiatrists will be able prescribe MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression.

If you have any further questions, please contact [email protected]

Link to RANZCP’s Psychedelic-Assisted Therapy Information Hub.